SCHEMBL30771213

SCHEMBL30771213

O=C(O)c1cccc2c(-c3cn[nH]c3)c[nH]c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ CCNT1 O60563 1/20 0.40
▸ CCNK O75909 1/20 0.40
▸ CDK7 P50613 1/20 0.40
▸ CDK9 P50750 1/20 0.40
▸ CCNH P51946 1/20 0.40
▸ MNAT1 P51948 1/20 0.40
▸ CDK12 Q9NYV4 1/20 0.40
▸ AKT1 P31749 1/20 0.40
▸ AKT2 P31751 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ PIM1 P11309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29550614 0.77 AKT1 (0.58) SMN1; SMN2KDM4EALDH1A1AKT1AKT2
SCHEMBL2397762 0.77 AKT1 (0.58) SMN1; SMN2KDM4EALDH1A1AKT1AKT2
SCHEMBL26698220 0.77 ROCK1 (0.59) AKT1ROCK2ROCK1
SCHEMBL26698237 0.77 ROCK1 (0.59) AKT1ROCK2ROCK1
SCHEMBL30771367 0.77 ROCK1 (0.59) AKT1ROCK2ROCK1
SCHEMBL30771354 0.77 ROCK1 (0.59) AKT1ROCK2ROCK1
SCHEMBL30771333 0.77 ROCK1 (0.59) AKT1ROCK2ROCK1
SCHEMBL28156349 0.77 AKT1 (0.44) AKT1AKT2ROCK2ROCK1GPR35
SCHEMBL26698252 0.77 IMPDH2 (0.63) CCNT1CCNKCDK9CDK12AKT1
SCHEMBL17799585 0.76 AKT1 (0.56) SMN1; SMN2KDM4EALDH1A1AKT1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-11-13 — — US disclosed
EP-4532484-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-04-09 — — EP disclosed
CN-119173509-A ROCK inhibitors and uses thereof 迪哲(江苏)医药股份有限公司 2024-12-20 — — CN disclosed
WO-2023226965-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF ROCK1, ROCK2, RHOA HTT 3843/4885SMN1; SMN2 4305/4885KDM4E 2213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback